{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:18:52Z","timestamp":1764890332347,"version":"3.46.0"},"reference-count":29,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer poses a significant threat to public health, as demonstrated by its high incidence rate. While postoperative radiotherapy remains an important adjuvant treatment for patients with breast cancer undergoing breast-conserving surgery, radiation-induced dermatitis (RID) is a prevalent side effect, for which no standardised prevention method currently exists. Our previous preclinical research demonstrated that ursodeoxycholic acid (UDCA) significantly reduced radiation-induced skin damage in mice. Therefore, this phase I\/II clinical study aims to further evaluate the safety and efficacy of UDCA in preventing RID during adjuvant radiotherapy in patients with breast cancer after breast-conserving surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This single-centre phase I\/II clinical study, with a single-arm cohort design in phase II, will include female patients who have undergone adjuvant radiotherapy after breast-conserving surgery for breast cancer. The sample size for the study is 40. Eligible patients will receive adjuvant radiotherapy at a prescribed dose of 50\u2009Gy\/25 F to the entire breast and lymphatic drainage area, where indicated, and 66\u2009Gy\/33 F to the tumour bed. After each irradiation, a 250\u2009mg dose of UDCA will be topically administered to the irradiated area. Radiological dermatitis and skin temperature were assessed once a week after the initiation of radiotherapy, and haematological toxicity, radiation lung injury and quality of life were monitored and analysed on a regular basis until the second week after the conclusion of radiotherapy. The primary objectives of phase I and II studies are the safety profile and incidence of grade II or higher RID in patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the ethics committee of Mianyang Central Hospital, China (No: S20230211-02) and is registered in the Chinese Clinical Trial Register (registration number: ChiCTR2400085925). Results will be published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2400085925.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098678","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:00:29Z","timestamp":1761033629000},"page":"e098678","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Ursodeoxycholic acid for the prevention of severe radiation dermatitis: a single-arm phase I\/II trial protocol in patients with breast cancer undergoing postoperative radiotherapy in China"],"prefix":"10.1136","volume":"15","author":[{"given":"Xinlan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"},{"name":"Department of Oncology, Mianyang Central Hospital, Mianyang, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binwei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mianyang Central Hospital, Mianyang, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixue","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mianyang Central Hospital, Mianyang, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunyuan","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"},{"name":"Department of Oncology, Mianyang Central Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Mianyang Orthopaedic Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Mianyang Orthopaedic Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-0636","authenticated-orcid":false,"given":"Xiaobo","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mianyang Central Hospital, Mianyang, Sichuan, China"},{"name":"Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"2025120415080440000_15.10.e098678.1","doi-asserted-by":"crossref","first-page":"e978","DOI":"10.1016\/S2214-109X(20)30307-7","article-title":"Global disparities in breast cancer outcomes: new perspectives, widening inequities, unanswered questions","volume":"8","author":"Oluwasanu","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2025120415080440000_15.10.e098678.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71156-8"},{"key":"2025120415080440000_15.10.e098678.3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2015.5805","article-title":"Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review","volume":"2","author":"Speers","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025120415080440000_15.10.e098678.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10285-0","article-title":"Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy","volume":"22","author":"Lee","year":"2022","journal-title":"BMC Cancer"},{"key":"2025120415080440000_15.10.e098678.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102028","article-title":"Radiation-induced dermatitis among breast cancer patients undergoing adjuvant radiotherapy in Ghana","volume":"46","author":"Kyei","year":"2024","journal-title":"Transl Oncol"},{"key":"2025120415080440000_15.10.e098678.6","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1203_22"},{"key":"2025120415080440000_15.10.e098678.7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00066-022-01985-4","article-title":"Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity","volume":"199","author":"Ben Amor","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"2025120415080440000_15.10.e098678.8","doi-asserted-by":"publisher","DOI":"10.1188\/04.ONF.237-247"},{"key":"2025120415080440000_15.10.e098678.9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/0971-653X.121877","article-title":"Radiation dermatitis: An overview","volume":"21","author":"Khanna","year":"2013","journal-title":"Indian J Burns"},{"key":"2025120415080440000_15.10.e098678.10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ijrobp.2010.01.031","article-title":"Mometasone Furoate Effect on Acute Skin Toxicity in Breast Cancer Patients Receiving Radiotherapy: A Phase III Double-Blind, Randomized Trial From the North Central Cancer Treatment Group N06C4","volume":"79","author":"Miller","year":"2011","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2025120415080440000_15.10.e098678.11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12282-022-01403-8","article-title":"The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis","volume":"30","author":"Sekiguchi","year":"2023","journal-title":"Breast Cancer"},{"key":"2025120415080440000_15.10.e098678.12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-017-0006-x","article-title":"Vitamin D ointment for prevention of radiation dermatitis in breast cancer patients","volume":"3","author":"Nasser","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"2025120415080440000_15.10.e098678.13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ijrobp.2014.06.033","article-title":"Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Patients Receiving Breast Radiation Therapy: Results of a Randomized Trial","volume":"90","author":"Hindley","year":"2014","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2025120415080440000_15.10.e098678.14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1188\/20.ONF.654-670","article-title":"ONS Guidelines for Cancer Treatment-Related Radiodermatitis","volume":"47","author":"Gosselin","year":"2020","journal-title":"Oncol Nurs Forum"},{"key":"2025120415080440000_15.10.e098678.15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.prro.2021.05.005","article-title":"ASTRO Editorial: ONS Guidelines for Cancer Treatment-Related Radiodermatitis","volume":"11","author":"Marquez","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"2025120415080440000_15.10.e098678.16","first-page":"46","article-title":"Roles of ursodeoxycholic acid in the bile biochemistry and metabolomics in patients with choledocholithiasis: a prospective study","volume":"18","author":"Guan","year":"2022","journal-title":"Metabolomics (Los Angel)"},{"key":"2025120415080440000_15.10.e098678.17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2024.01.030","article-title":"Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid","volume":"124","author":"van Hooff","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025120415080440000_15.10.e098678.18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000371904","article-title":"Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders","volume":"33","author":"Trauner","year":"2015","journal-title":"Dig Dis"},{"key":"2025120415080440000_15.10.e098678.19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744488","article-title":"Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review","volume":"12","author":"Robles-D\u00edaz","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025120415080440000_15.10.e098678.20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J Hepatol"},{"key":"2025120415080440000_15.10.e098678.21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S2468-1253(21)00301-0","article-title":"Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial","volume":"6","author":"Haal","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120415080440000_15.10.e098678.22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.toxlet.2014.10.011","article-title":"Diet supplementation with cholic acid promotes intestinal epithelial proliferation in rats exposed to \u03b3-radiation","volume":"232","author":"Hagio","year":"2015","journal-title":"Toxicol Lett"},{"key":"2025120415080440000_15.10.e098678.23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09553002.2023.2245461","article-title":"Altered bile acid metabolism in skin tissues in response to ionizing radiation: deoxycholic acid (DCA) as a novel treatment for radiogenic skin injury","volume":"100","author":"Zhang","year":"2024","journal-title":"Int J Radiat Biol"},{"key":"2025120415080440000_15.10.e098678.24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2019.08.007","article-title":"Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial","volume":"142","author":"Elbers","year":"2020","journal-title":"Radiother Oncol"},{"key":"2025120415080440000_15.10.e098678.25","first-page":"863","article-title":"National Cancer Center \/ National Cancer Quality Control Center. Guideline of target delineation and treatment planning of adjuvant radiotherapy for breast cancer","volume":"31","year":"2022","journal-title":"Chin J Radiat Oncol"},{"key":"2025120415080440000_15.10.e098678.26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.colsurfa.2017.01.023","article-title":"Wax adsorption at paraffin oil\u2013water interface stabilized by Span80","volume":"518","author":"Ma","year":"2017","journal-title":"Colloids and Surfaces A: Physicochemical and Engineering Aspects"},{"key":"2025120415080440000_15.10.e098678.27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.colsurfa.2016.06.042","article-title":"Emulsion stability of surfactant and solid stabilized water-in-oil emulsions after hydrate formation and dissociation","volume":"506","author":"Yegya Raman","year":"2016","journal-title":"Colloids and Surfaces A: Physicochemical and Engineering Aspects"},{"key":"2025120415080440000_15.10.e098678.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.08.071"},{"key":"2025120415080440000_15.10.e098678.29","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509x.29424"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:13:54Z","timestamp":1764890034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2024-098678"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098678","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}